# Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain

> **NCT01337089** · PHASE3 · COMPLETED · sponsor: **Jazz Pharmaceuticals** · enrollment: 660 (actual)

## Conditions studied

- Pain
- Advanced Cancer

## Interventions

- **DRUG:** Nabiximols

## Key facts

- **NCT ID:** NCT01337089
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-19
- **Primary completion:** 2016-01-27
- **Final completion:** 2016-01-27
- **Target enrollment:** 660 (ACTUAL)
- **Last updated:** 2023-04-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01337089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01337089, "Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01337089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*